Propanc Biopharma gets notice of allowance for Proenzyme Composition patent

Propanc Biopharma ( OTCPK:PPCB ) on Wednesday announced that it received the allowance for the company's "proenzyme composition" patent from the Canadian Intellectual Property Office. The patent broadly captures both high dose and high ratio claims for future clinical doses of the company’s lead asset, PRP. This is the second Canadian patent either allowed or granted in this important North American jurisdiction.

Press release. More on Propanc Biopharma, Inc. Financial information for Propanc Biopharma, Inc.

.